Enzon, Zhejiang Hisun Pharmaceutical deal
Enzon will use its PEGylation Linker Technology to develop PEGylated versions of selected candidates from Hisun. The pharma will have an option to license the therapeutics in China, where it will be responsible for further development and commercialization. Enzon will be eligible for milestone payments and royalties from products developed in China and will retain rights to the compounds outside of China.
Additionally, Enzon granted Hisun exclusive rights in China to develop and commercialize PEG-SN38. Enzon will receive an upfront payment and is eligible for milestone payments and high-single-digit royalties. PEG-SN38 completed Phase II testing in the U.S. for metastatic breast cancer, colon cancer and solid tumors in pediatric patients. PEG-SN38 is a pegylated form of SN38, the active metabolite of irinotecan. Details were not disclosed. ...